Revefenacin Impurity 35 | CAS 375359-83-4 - Request Quote
Revefenacin Impurity 35
| SZ CAT No: | SZ-R043046 |
| CAS No | 375359-83-4 |
| Mol.F. | C8H13ClN2O2 |
| Mol.Wt. | 204.7 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Revefenacin Impurity 35 is chemically 1-(2-Chloroacetyl)piperidine-4-carboxamide. Revefenacin Impurity 35 is supplied with detailed characterization data compliant with regulatory guideline. Revefenacin Impurity 35 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Revefenacin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 375359-83-4
Purchase 375359-83-4
Order 375359-83-4
Enquire 375359-83-4
price of 375359-83-4
375359-83-4 Supplier
375359-83-4 Manufacturer
375359-83-4 Exporter
buy high quality Revefenacin Impurity 35
Purchase Revefenacin Impurity 35
Revefenacin Impurity 35 suppliers
Revefenacin Impurity 35 manufacturers
Revefenacin Impurity 35 price
Order Revefenacin Impurity 35
Enquire Revefenacin Impurity 35
Revefenacin Impurity 35 cost
Revefenacin Impurity 35 Supplier
Revefenacin Impurity 35 Distributor
Revefenacin Impurity 35 for Method Validation
Revefenacin Reference Standard
Revefenacin Impurity 35 for ANDA Filing
Revefenacin Impurity 35 for Forced Degradation Studies
Revefenacin Impurity 35 Identification Standards
Revefenacin Impurity 35 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.